Expert Interview
Discussing Boehringer Ingelheim’s FDA Approval of JASCAYD® (Nerandomilast) for Progressive Pulmonary Fibrosis
Ticker(s): BOEHRINGER INGELHEIMUniversity of Oklahoma Health Sciences Center
- Associate Professor and Pulmonary & Critical Care Physician at OU Health and OU College of Medicine, Director of the Interstitial Lung Disease Program.
- Manages 250 PPF patients yearly (80% have been prescribed antibiotics). Treats 100+ patients per year with advanced lung diseases, interstitial lung disease, pulmonary fibrosis, sarcoidosis, and related pulmonary conditions through outpatient and specialized clinic care (exact annual patient number not publicly specified).
- Specializes in caring for people with advanced lung diseases and interstitial lung disease; leads Oklahoma’s first comprehensive ILD program, participates in clinical trials and multidisciplinary research initiatives, and focuses on personalized, evidence-based approaches to diagnosing and managing complex pulmonary conditions.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
